Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.09) by 16.51 percent. This is a 26.02 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $31.738 million which beat the analyst consensus estimate of $10.977 million by 189.12 percent. This is a 324.87 percent increase over sales of $7.470 million the same period last year.